U.S. Oil and Gas Stock News

Intrepid Potash (IPI) has drawn fresh investor attention after reporting fourth quarter 2025 results that reduced its net loss to US$0.429 million and confirming plans to enter lithium production through the White Silver Lithium Project. See our latest analysis for Intrepid Potash. The share price has been building momentum, with a 30 day share price return of 26.71% and a 90 day share price return of 56.14%, while the 1 year total shareholder return sits at 45.02%. This reflects growing...

Waste Management (NYSE:WM) has formally recognized outgoing CFO Devina Rankin for her leadership in integrating the Healthcare Solutions business following the Stericycle acquisition. The acknowledgment also highlights her role in supporting the management transition as the company moves to a new CFO. This recognition underscores the importance of the Stericycle deal and the new Healthcare Solutions segment in Waste Management's business mix. For investors watching NYSE:WM, this leadership...

On March 12, 2026, Axcelis Technologies announced that Senior Vice President of Investor Relations and Corporate Strategy David Ryzhik was appointed Interim Chief Financial Officer, replacing departing CFO James Coogan, who will remain until April 24, 2026 to support the handover. The move places a long‑tenured finance and investor relations specialist at the center of Axcelis’s financial leadership, potentially sharpening how the company aligns capital allocation, messaging, and corporate...

CSX expanded its Select Site initiative by awarding its designation to 21 new rail served properties across 10 states. Owens Corning announced a large manufacturing investment at a CSX Silver Select Site in Alabama, tied to about 100 new skilled jobs. This development reflects fresh industrial interest in CSX served locations, beyond recent discussions focused on valuation, margin outlook, and service metrics for NasdaqGS:CSX. For investors tracking NasdaqGS:CSX, this move adds a fresh...

In March 2026, Aldeyra Therapeutics reported that the FDA issued a Complete Response Letter for its reproxalap dry eye disease NDA, citing insufficient and inconsistent evidence of efficacy despite no safety or manufacturing concerns. An important nuance is that the FDA did not request new trials, instead urging Aldeyra to clarify why certain studies failed and where reproxalap might work best. We’ll now examine how the FDA’s efficacy concerns and lack of requested new trials reshape...

Johnson Controls International (NYSE:JCI) has agreed to sell its residential HVAC business to Bosch, reallocating focus toward data center and service solutions. The company is expanding offerings for AI oriented data centers, including a partnership with NVIDIA to support advanced cooling needs. Management has highlighted backlog growth as evidence of strong demand for these focus areas. For investors tracking NYSE:JCI, this shift comes with the stock at $132.56 and a 1 year return of...

Traeger, Inc. has already implemented a 1-for-50 reverse stock split on March 18, 2026, following stockholder approval earlier in the month to address a New York Stock Exchange notice that its shares had traded below US$1.00 for 30 consecutive trading days. This reverse split, combined with recent weak 2025 results and ongoing losses, highlights how Traeger is using financial tools rather than operational improvements alone to preserve its exchange listing. Next, we'll explore how Traeger's...

Before deciding whether Brightstar Lottery looks attractively priced, it helps to pin down what you are really getting for each dollar of its current US$12.74 share price. The stock has seen a 0.2% slip over the last week, a 5.3% decline over the last month, and is down 16.7% year to date, with a 4.7% decline over the last 12 months and a 32.7% decline over 3 years, even though the 5 year return sits at 7.0%. These mixed returns frame the key question of whether recent weakness reflects...

Comtech Telecommunications (CMTL) has just posted Q2 2026 results that keep the focus squarely on profitability, with Q1 2026 revenue of US$111.0 million, a basic EPS loss of US$0.67, and net income loss of US$19.8 million. Over recent quarters the company has seen revenue move from US$115.8 million and an EPS loss of US$52.93 in Q1 2025 to US$130.4 million and an EPS loss of US$0.39 in Q4 2025, with net income losses shifting from US$155.9 million to US$11.6 million across the same period...

Monte Rosa Therapeutics (GLUE) just posted its FY 2025 third quarter numbers, with revenue of US$12.8 million and a basic EPS loss of US$0.33 off a net income loss of US$27.1 million, setting a clear snapshot of where the business stands today. Over recent periods, the company has seen revenue move from US$60.6 million in Q4 2024 to US$84.9 million in Q1 2025, then to US$23.2 million in Q2 2025 and US$12.8 million in Q3 2025. Over the same timeframe, basic EPS shifted from a profit of US$0.16...

Embassy Bancorp (EMYB) has posted a clean set of Q3 2025 numbers, with total revenue of US$11.7 million and basic EPS of US$0.50, against a 12 month backdrop where revenue on a trailing basis moved from US$39.8 million to US$44.0 million and EPS from US$1.37 to US$1.68. The latest quarter sits within a year where earnings grew 21.3% versus the longer term trend and sets the stage for investors to focus on how a 29.1% net margin and a 2.58% net interest margin shape the quality and resilience...

Kaspi.kz (NasdaqGS:KSPI) has posted its FY 2025 results with Q4 revenue at KZT 1.1t and net income at KZT 276,983 million, translating into basic EPS of KZT 1,451.81, against a backdrop of trailing 12 month revenue of KZT 4.0t and net income of KZT 1,073,177 million. Over recent periods, the company has seen revenue move from KZT 744,178 million in Q4 2024 to KZT 1,146,548 million in Q4 2025, while quarterly basic EPS shifted from KZT 1,641.41 to KZT 1,451.81 and trailing basic EPS moved from...

Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these...

Stoke Therapeutics (STOK) has reported FY 2025 results that feature a wide range of quarterly outcomes. Q1 revenue was US$158.6 million with EPS of US$1.95, followed by Q2 revenue of US$13.8 million and an EPS loss of US$0.40, and Q3 revenue of US$10.6 million with an EPS loss of US$0.65. Over recent periods the company has seen revenue move between US$4.8 million and US$158.6 million per quarter, while EPS has shifted from a US$2.07 loss in FY 2024 to a US$1.95 profit and then back into...

WW International (WW) has just posted its FY 2025 results with Q3 revenue of US$172.1 million and a basic EPS loss of US$1.04, set against a trailing 12 month net income of about US$1.1 billion that reflects a large one off gain. Over recent quarters the company has seen revenue move between US$184.4 million and US$202.1 million, while EPS has swung from a profit of US$0.31 to a loss of US$0.91 and then a very large profit of US$15.71. This pattern points to margins that appear to be heavily...

Earlier this week, Savers Value Village reported preliminary fourth-quarter results showing an 8.8% rise in U.S. comparable sales and 0.7% growth in Canada, while President and COO Jubran N. Tanious exercised options for 100,000 shares at US$1.41 and sold 45,000 shares for about US$373,644 on March 11, 2026. This combination of stronger U.S. store performance and fresh insider share activity offers investors new information on both operational momentum and executive incentives. We’ll now...

Q3 2026 snapshot: Value Line (VALU) leans on margins as earnings trends soften Value Line (VALU) has just reported its Q3 2026 results, with recent quarters showing revenue around US$8.6 million and basic EPS between US$0.42 and US$0.69, while trailing twelve month EPS sits a little above US$2.25. Over the last six reported quarters, revenue has ranged from US$8.39 million to US$8.97 million and basic EPS has moved between US$0.42 and US$0.69, setting up a picture where high profitability...

Coya Therapeutics (COYA) has released its FY 2025 results, reporting fourth quarter revenue of US$4.0 million and a basic EPS loss of US$0.34, alongside trailing twelve month revenue of US$7.9 million and a basic EPS loss of US$1.27. The company’s revenue increased from US$0.00 million in the third quarter of 2024 to US$3.6 million in the third quarter of 2025, while quarterly basic EPS has ranged from a loss of US$0.44 in the first quarter of 2025 to a loss of US$0.13 in the third quarter of...

Zomedica (OTCPK:ZOMD.F) has reported its FY 2025 third quarter with total revenue of US$8.1 million and a basic EPS loss of US$0.006, alongside a net loss of US$6.1 million. Over recent quarters, revenue has moved from US$6.1 million in Q2 2024 to US$6.5 million in Q1 2025 and US$8.1 million in Q3 2025, while quarterly net losses have ranged from US$6.1 million to US$63.8 million and trailing twelve month revenue has reached US$29.5 million against a trailing net loss of US$84.5 million. For...

Consolidated Water (CWCO) has put up another solid top line in FY 2025 so far, with Q3 revenue of about US$35.1 million and basic EPS of roughly US$0.35, while the latest trailing twelve months show revenue of about US$130.8 million and EPS of around US$1.09. Over recent periods the company has seen revenue move from roughly US$28.4 million in Q4 2024 to US$35.1 million in Q3 2025, with quarterly EPS shifting from about US$0.11 to US$0.35 over the same stretch. This sets up a story where...

The FDA approved an updated label for Krystal Biotech's Vyjuvek (beremagene geperpavec svdt) for epidermolysis bullosa. KB803 progressed as an emerging therapy candidate in Krystal Biotech's pipeline. These developments affect the treatment options available for epidermolysis bullosa and the outlook for NasdaqGS:KRYS. Krystal Biotech, listed on NasdaqGS:KRYS, focuses on gene therapies for rare skin conditions such as epidermolysis bullosa. With Vyjuvek already in the market and KB803 moving...

Bumble (BMBL) has wrapped up FY 2025 with fourth quarter revenue of US$224.2 million and a basic EPS loss of US$4.06, alongside a net income loss of US$499.4 million. Over recent periods the company has seen quarterly revenue move from US$261.6 million in Q4 2024 to US$247.1 million in Q1 2025, US$248.2 million in Q2, US$246.2 million in Q3, and US$224.2 million in Q4. EPS swung between a profit of US$0.34 in Q3 and losses such as US$2.45 in Q2 and US$4.06 in Q4, setting up a story that is as...

Summit Midstream (SMC) has reported third quarter FY 2025 revenue of US$138.0 million with a basic EPS loss of US$0.13, as continued losses keep profitability in focus for investors. The company has seen revenue move from US$93.2 million in Q2 FY 2024 to US$138.0 million in Q3 FY 2025, while basic EPS over the same stretch has ranged from a loss of US$19.25 per share in Q3 FY 2024 to a loss of US$0.13 per share in the latest quarter, keeping margins firmly in the red and the quality of the...

Latest FY 2025 earnings snapshot Security National Financial (SNFC.A) closed FY 2025 with fourth quarter revenue of US$83.0 million and basic EPS of US$0.55, alongside trailing 12 month figures of US$344.6 million in revenue and EPS of US$1.30 that sit against earnings growth of 21.2% over the past year. Over recent periods, revenue has moved from US$79.3 million and EPS of effectively zero in Q4 2024 to US$83.0 million and EPS of US$0.55 in Q4 2025. Trailing net income reached US$32.2...